A new April 13, 2026 medRxiv preprint found that tirzepatide was associated with greater relative lean-body-mass loss than semaglutide in routine care, with excess lean-body-mass losses of 1.1%, 1.5%, 1.3%, and 2.0% at 3, 6, 9, and 12 months, respectively. It also found a more aggressive high-loss pattern in 10.3% of tirzepatide users versus 6.7% of semaglutide users. [0]
That is a real signal worth paying attention to. It is not the same thing as proof that Zepbound directly destroys muscle. The study was observational, it has not been peer reviewed yet, and lean body mass is not the same thing as skeletal muscle. Lean mass also includes water, organs, bone, and other non-fat tissue. [5]
The practical takeaway is simpler than the headline: if you are losing weight quickly on tirzepatide or semaglutide, you need a better muscle-protection plan, not panic. This guide breaks down what the new study actually found, what it does not prove, and what to do next. For the broader context, see our guides to GLP-1 muscle loss, exercise on GLP-1 medications, and tirzepatide vs. semaglutide.
What The New April 2026 Study Actually Found
The new paper was posted on medRxiv on April 13, 2026 and looked at electronic-health-record-linked body-composition data in routine care. The authors started with a very large pool of first-episode GLP-1 receptor agonist users, then analyzed 7,965 people who had paired body-composition measurements before and after treatment start. [0]
The most cited findings were these:
- Tirzepatide was associated with more relative lean-body-mass loss than semaglutide at every measured time point in the first year. [0]
- By 12 months, the excess relative lean-body-mass decline with tirzepatide was 2.0 percentage points. [0]
- A “depletive” pattern, defined by the authors as more than 20% total body-weight loss plus more than 5% lean-body-mass loss, occurred in 10.3% of tirzepatide users versus 6.7% of semaglutide users. [0]
- Reduced exercise tolerance and baseline musculoskeletal pain were linked with greater lean-body-mass loss, which fits the common-sense idea that people who move less or train less may be more vulnerable during fast weight loss. [0]
Those findings matter because they shift the discussion away from “did the scale go down?” and toward “what exactly went down with it?”
What The Study Does Not Prove
This is the section the headlines usually skip.
1. It does not prove direct muscle loss
The study measured lean body mass, not biopsy-confirmed muscle loss and not a full battery of strength and functional outcomes. That distinction matters. As Tinsley and Heymsfield emphasize, fat-free mass and lean-mass changes are often discussed as if they were identical to skeletal-muscle changes, but they are not. [5]
2. It does not separate drug effect from weight-loss magnitude cleanly
Tirzepatide usually causes greater total weight loss than semaglutide. In the 2025 head-to-head obesity trial, week-72 weight change was -20.2% with tirzepatide versus -13.7% with semaglutide. [1] When one drug drives larger overall losses, it is not surprising to also see larger lean-mass changes unless diet, protein intake, training status, and physical function are all controlled carefully.
3. It is not yet peer reviewed
The preprint is useful because it is current and large, but it is still a preprint. That means methods, interpretation, and even some conclusions may change after peer review. [0]
Why The Headline Is Plausible But Still Needs Context
The new preprint is not coming out of nowhere. Earlier studies already suggested that larger weight-loss responses often come with lean-mass loss unless the reader protects against it.
In the SURMOUNT-1 body-composition substudy, tirzepatide reduced body weight by 21.3%, fat mass by 33.9%, and lean mass by 10.9% over 72 weeks. Roughly 75% of the lost weight was fat mass and 25% was lean mass. [2]
In the STEP 1 exploratory body-composition analysis, semaglutide reduced body weight by 15.0%, total fat mass by 19.3%, and total lean body mass by 9.7%, while the proportion of lean body mass relative to total body mass actually increased by 3.0 percentage points. [3]
And in the newer SEMALEAN study of semaglutide 2.4 mg, lean mass dropped by about 3 kg at 7 months and then stabilized, while handgrip strength improved by 4.5 kg at 12 months and sarcopenic obesity became less common over time. [4]
That is why the best reading of the April 2026 preprint is not “tirzepatide is toxic to muscle.” The better reading is: faster and more powerful weight loss may create a bigger lean-mass-management problem unless patients also protect function, protein intake, and training.
A Better Way To Read Lean-Mass Headlines
Use this table as your filter before you panic.
| Headline claim | Better interpretation |
|---|---|
| ”Tirzepatide causes more muscle loss than semaglutide.” | The new preprint found more relative lean-body-mass decline, not definitive proof of worse skeletal-muscle function. [0] [5] |
| “More lean-mass loss means the drug is unsafe.” | Not necessarily. Many effective weight-loss interventions reduce some lean mass. The real question is how much is fat, how much is lean tissue, and whether strength and physical function are falling. [2] [3] [5] |
| “Wegovy is safer for muscle than Zepbound.” | Too early to say that cleanly. Semaglutide has some reassuring body-composition data, but the new comparison signal still needs peer-reviewed confirmation and better functional testing. [0] [4] |
| “If lean mass drops, nothing can be done.” | Wrong. Higher protein intake and resistance training remain the most practical countermeasures we have. [6] [7] [8] |
What To Do If You Are On Wegovy Or Zepbound Right Now
Most readers do not need a debate about receptor biology. They need a plan.
1. Stop treating appetite suppression like a free win
If your weight is dropping quickly but your food intake has quietly collapsed, you are the exact person who should care about this paper. Fast weight loss without enough protein or enough loading exercise is where lean-mass headlines become more relevant in real life.
2. Set a protein floor
The recent review Protein requirement in obesity argues that during weight loss, about 1.2 g/kg/day is a reasonable floor, especially when the goal is to preserve lean tissue. [6] The Ogilvie analysis also found that adults eating about 1.0 g/kg/day during caloric restriction had less lean-body-mass loss than those closer to 0.8 g/kg/day. [7]
That does not mean you need a perfect bodybuilding meal plan. It means under-eating protein on a GLP-1 is usually the wrong move.
3. Lift something twice a week
The resistance-training meta-analysis by Lopez and colleagues found that resistance training was the most effective exercise approach for increasing lean mass, and that lean mass was generally maintained when resistance training was paired with caloric restriction. [8]
For most readers, the minimum useful plan is:
2 full-body strength sessions per week4 to 6 hard setsper major muscle group per week- a simple focus on squat or leg press, hinge, push, pull, and core or carry work
That is enough to matter. You do not need a five-day split to get most of the protective effect.
4. Watch function, not just scans
The more meaningful red flags are not just “my DXA changed.” They are:
- your lifts are sliding week after week
- stairs feel harder than they did a month ago
- you are skipping meals because everything sounds unappealing
- you feel weaker, not just lighter
Those are the moments to tighten the nutrition and training plan, or to talk with your prescriber about whether the pace of loss has outstripped recovery.
Who Should Take This Signal Most Seriously
The new preprint specifically highlighted reduced exercise tolerance and musculoskeletal pain as markers linked with worse lean-body-mass outcomes. [0] That means the readers who should pay the closest attention are probably:
- older adults
- people with knee, hip, or back pain who already move less
- people losing weight very quickly
- people with nausea, fatigue, or low appetite severe enough to cut protein intake
- anyone seeing obvious weakness along with rapid scale changes
That does not mean those patients should avoid treatment automatically. It means they may need a more deliberate muscle-preservation strategy from day one.
Bottom Line
The April 13, 2026 preprint is important because it adds a real-world warning signal: tirzepatide may be associated with greater lean-body-mass decline than semaglutide during the first year of treatment. [0]
But the strongest conclusion you can defend today is narrower than the headlines make it sound. The paper does not prove that Zepbound directly causes worse muscle loss than Wegovy. It does support a more practical point: the more powerful the weight-loss effect, the more seriously you need to take protein, strength training, and physical function while the scale is dropping.
If you want the shortest version:
- Do not confuse lean mass with pure muscle.
- Do not confuse a preprint with a settled verdict.
- Do treat rapid weight loss like something that needs a real muscle-protection plan.
